Protagonist Therapeutics Has Randomized 241 Patients In Phase 3 VERIFY Trial Of Rusfertide In Polycythemia Vera, Expects To Meet 250 Enrollment Target By End Of March, Topline Data Is Expected in Q1 2025
Protagonist Therapeutics Has Randomized 241 Patients In Phase 3 VERIFY Trial Of Rusfertide In Polycythemia Vera, Expects To Meet 250 Enrollment Target By End Of March, Topline Data Is Expected in Q1 2025
Protagonist Therapeutics已在治療真性紅細胞增多症的Rusfertide的3期VERIFY試驗中隨機分配了241名患者，預計到3月底將達到250名入組目標，頭條數據預計將於2025年第一季度公佈
Protagonist Therapeutics Has Randomized 241 Patients In Phase 3 VERIFY Trial Of Rusfertide In Polycythemia Vera, Expects To Meet 250 Enrollment Target By End Of March, Topline Data Is Expected in Q1 2025
Protagonist Therapeutics已在治療真性紅細胞增多症的Rusfertide的3期VERIFY試驗中隨機分配了241名患者，預計到3月底將達到250名入組目標，頭條數據預計將於2025年第一季度公佈
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。